Although the results shown here need to be validated in a larger cohort of CML patients, the administration of IFN-α might be a valuable strategy to boost immune surveillance, to possibly eradicate leukemic stem cells and to support TKI discontinuation, if associated with careful monitoring of immunosuppressive cells. The gene discussed is IFNA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.